VEGFA and neoplasm: Bevacizumab is the first humanized monoclonal antibody against tumor angiogenesis approved by the U.S. Food and Drug Administration, which can bind to VEGFA, reducing the binding of vascular endothelial growth factor to its receptor and thereby inhibiting vascular growth.